首页> 外文期刊>Therapeutic Drug Monitoring >Interference from digitoxin-like immunoreactive factors reduced in a new monoclonal chemiluminescent digitoxin assay.
【24h】

Interference from digitoxin-like immunoreactive factors reduced in a new monoclonal chemiluminescent digitoxin assay.

机译:在新的单克隆化学发光洋地黄毒蛋白测定中,减少了洋地黄毒素样免疫反应因子的干扰。

获取原文
获取原文并翻译 | 示例
       

摘要

Endogenous digoxin-like immunoreactive factors (DLIF) can interfere with some digoxin immunoassays. We looked for similar interference, called digitoxin-like immunoreactive factors (DTLIF) in two digitoxin immunoassays: A new chemiluminescent assay (CLIA), processed on the automated random access immunoassay system ACS:180, and a fluorescent polarization assay (FPIA), processed on the semiautomated TDx batch analyzer. One hundred thirty-seven samples of sera were tested from nondigitalized pregnant women, patients with liver or kidney diseases, and cord blood. The CLIA digitoxin assay uses a murine monoclonal antibody and requires no sample pretreatment; the FPIA digitoxin assay uses a polyclonal rabbit antibody and requires sample precipitation. Both assays have a similar dynamic range and sensitivity and give comparable results with commercial controls and external quality control survey samples. Although the CLIA detected no digitoxin in any sample tested, the FPIA showed apparent digitoxin concentrations of more than 2.0 ng/ml for 100% and 44% among cord blood and liver disease specimens, respectively. The highest DTLIF concentration was found in serum from a patient with liver disease (18.1 ng/ml). When spiked with 32 ng/ml digitoxin, six of the samples containing DTLIF generated FPIA digitoxin values of 6% to 27.5% more than the expected digitoxin levels. Two specimens with no detectable DTLIF activity were run as controls, and when spiked with digitoxin, showed target digitoxin concentrations in the FPIA. The CLIA recovered near the target digitoxin values (32 ng/ml) in all spiked samples. It was concluded that the polyclonal FPIA digitoxin assay may give discordant digitoxin concentrations in some patient groups because of interference from digitoxin-like immunoreactive factors. The CLIA digitoxin assay is not affected by DTLIF interference.
机译:内源性地高辛样免疫反应因子(DLIF)可能会干扰某些地高辛免疫测定。我们在两种洋地黄毒免疫分析中寻找类似的干扰,称为洋地黄毒样免疫反应因子(DTLIF):一种新的化学发光分析(CLIA),在自动随机存取免疫分析系统ACS:180上进行处理,以及荧光偏振化验(FPIA),在处理中在半自动TDx批次分析仪上。从未数字化的孕妇,患有肝肾疾病和脐带血的患者中测试了137份血清样品。 CLIA洋地黄毒蛋白测定法使用鼠类单克隆抗体,不需要样品预处理。 FPIA洋地黄毒蛋白测定法使用多克隆兔抗体,并且需要样品沉淀。两种测定法都具有相似的动态范围和灵敏度,并能与商业对照和外部质量控制调查样品提供可比的结果。尽管CLIA在任何测试样品中均未检测到洋地黄毒素,但FPIA在脐带血和肝病标本中分别显示出100%和44%的表观洋地黄毒素浓度均超过2.0 ng / ml。在患有肝病的患者的血清中发现最高的DTLIF浓度(18.1 ng / ml)。当掺入32 ng / ml洋地黄毒时,六个包含DTLIF的样品产生的FPIA洋地黄毒值比预期的洋地黄毒素水平高6%至27.5%。将两个没有可检测到的DTLIF活性的样品作为对照,当掺入洋地黄毒时,显示FPIA中目标洋地黄毒的浓度。在所有加标样品中,CLIA均恢复到目标洋地黄毒素值(32 ng / ml)附近。结论是,由于类似洋地黄毒素样免疫反应因子的干扰,多克隆FPIA洋地黄毒蛋白测定在某些患者组中可能会产生不一致的洋地黄毒蛋白浓度。 CLIA洋地黄毒苷测定不受DTLIF干扰的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号